| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9j9799C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0109799 |
| P932 | PMC publication ID | 4188578 |
| P698 | PubMed publication ID | 25289677 |
| P5875 | ResearchGate publication ID | 266625748 |
| P50 | author | Bader Alahmari | Q57032058 |
| Jaebok Choi | Q52430559 | ||
| P2093 | author name string | Matthew Holt | |
| John F DiPersio | |||
| Matthew L Cooper | |||
| Julie Ritchey | |||
| Lynne Collins | |||
| P2860 | cites work | An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin | Q71881409 |
| Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion | Q74477786 | ||
| Real-time imaging of ligand-induced IKK activation in intact cells and in living mice | Q81045070 | ||
| NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic | Q82884856 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. | Q27851427 | ||
| Interferon-γ: an overview of signals, mechanisms and functions | Q28207081 | ||
| The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors | Q33613105 | ||
| CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms | Q33944270 | ||
| In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. | Q33997187 | ||
| Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 | ||
| Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses | Q34033872 | ||
| The JAK/STAT signaling pathway | Q34305849 | ||
| Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13 | Q34541778 | ||
| Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression | Q34755408 | ||
| The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. | Q35664956 | ||
| IFNγR signaling mediates alloreactive T-cell trafficking and GVHD | Q36395621 | ||
| Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. | Q36776428 | ||
| AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors | Q37038472 | ||
| Myeloid-derived suppressor cells in breast cancer | Q37172813 | ||
| Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease | Q37373067 | ||
| New perspectives on the biology of acute GVHD. | Q37641063 | ||
| Recent patents in the discovery of small molecule inhibitors of JAK3. | Q37733546 | ||
| The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia | Q38064832 | ||
| Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo | Q39017147 | ||
| Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation | Q40517810 | ||
| Regulation of MHC class I and II gene transcription: differences and similarities | Q42681956 | ||
| High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression | Q44443187 | ||
| Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism | Q47745301 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| pharmacology | Q128406 | ||
| P304 | page(s) | e109799 | |
| P577 | publication date | 2014-10-07 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | |
| P478 | volume | 9 |
| Q49645938 | Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications |
| Q99721339 | Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study |
| Q52310616 | Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. |
| Q37522548 | Biology of chronic graft-vs-host disease: Immune mechanisms and progress in biomarker discovery. |
| Q37638846 | CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. |
| Q47114304 | Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis. |
| Q38786084 | Emerging drugs for graft-versus-host disease |
| Q37114440 | Immunological basis for treatment of graft versus host disease after liver transplant |
| Q91587430 | Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib |
| Q39002166 | Mechanistic approaches for the prevention and treatment of chronic GVHD. |
| Q49238507 | New and emerging therapies for acute and chronic graft versus host disease |
| Q39023963 | Novel targets in the treatment of chronic graft-versus-host disease |
| Q54186062 | Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. |
| Q91844259 | Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib |
| Q26851417 | Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors |
| Q96431807 | Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients |
| Q92528596 | Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation |
| Q48231285 | Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease |
| Q64055485 | Ruxolitinib for Therapy of Graft-versus-Host Disease |
| Q50115590 | Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials |
| Q91174334 | Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study |
| Q92327065 | Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT |
| Q49724160 | Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease |
| Q37302887 | Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials |
| Q60938512 | Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease |
| Q55060181 | T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation. |
| Q52927960 | Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. |
| Q59800879 | Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD |
| Q48139357 | Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. |
| Q92569958 | The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review |
| Q64257524 | The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease |
| Q49384876 | The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. |
Search more.